Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.33 |
| ▸ | CASP7 | P55210 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9538524 | 0.76 | GRM5 (0.40) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL17654205 | 0.75 | GBA1 (0.44) | ALDH1A1KDM4EGRM5GBA1SMN1; SMN2 | |
| SCHEMBL3129653 | 0.74 | HSD17B10 (0.50) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL19276438 | 0.72 | HSD17B10 (0.48) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL30775296 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL29294865 | 0.72 | HSD17B10 (0.48) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL13556548 | 0.72 | HSD17B10 (0.48) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL3129639 | 0.72 | HSD17B10 (0.48) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL4926690 | 0.72 | HSD17B10 (0.54) | ALDH1A1HSD17B10KDM4EALOX15GRM5 | |
| SCHEMBL5132886 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HSD17B10KDM4EALOX15GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117810541-A | Nonaqueous magnesium electrolyte and preparation method thereof | 青岛科技大学 | 2024-04-02 | — | — | CN | claimed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4061813-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-117810541-B | Nonaqueous magnesium electrolyte and preparation method thereof | 青岛科技大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| EP-0821683-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1998-02-04 | — | — | EP | disclosed |
| EP-0821684-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A? RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033194-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996033192-A1 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 1996-10-24 | — | — | WO | disclosed |
| US-5304647-A | Addition of an organolithium reagent; dehydrogenation of addition product; two-phase conditions prevents hydrolysis | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1994-04-19 | — | — | US | disclosed |
| EP-0544705-A1 | DERIVATIVES OF MUPIROCIN | Beecham Group p.l.c. (GB) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992002518-A1 | DERIVATIVES OF MUPIROCIN | BEECHAM GROUP PLC (GB) | 1992-02-20 | — | — | WO | disclosed |
| US-4963676-A | INTERMEDIATES FOR NOVEL UNFUSED HETEROBICYCLIC COMPOUNDS WITH BIOLOGICAL ACTIVITY; ANTICANCER AGENTS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4929726-A | ANTICARCINOGENIC AGENTS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1990-05-29 | — | — | US | disclosed |
| WO-1989007599-A2 | NOVEL DIAZINES AND THEIR METHOD OF PREPARATION | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | ALDH1A1 1598/4885HSD17B10 2146/4885KDM4E 2420/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3415/4885HSD17B10 3321/4885KDM4E 868/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | ALDH1A1 3927/4885HSD17B10 289/4885KDM4E 4591/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 2338/4885HSD17B10 1063/4885KDM4E 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.